Start · Catalogue · Profile · Table
Supplements BODY HANDBOOK
Supplements · §522
Medicinal Mushrooms (Lion's Mane, Reishi, Cordyceps, Turkey Tail, Chaga)
A bottle of lion's mane for focus, a tin of reishi for sleep, cordyceps for the afternoon dip — the functional-mushroom aisle has tripled since 2020 and most of what's on it does less than the label promises. Two species earn their place: lion's mane for the cognitive slippage that creeps into midlife, and turkey tail's patented PSK extract as a chemotherapy adjuvant under an oncologist. The rest — reishi, cordyceps, chaga — carries centuries of tradition and a handful of small trials, sold much harder than it has been studied. The decision before all of them is harder than which species: most retail powder is not the mushroom on the label.
Decide · Daily Evidence Mixed Chapter Supplements

Lion's mane at a gram or two a day has small but consistent trials in older adults with creeping mental sluggishness — a slow restorative, not a smart drug. Cordyceps may add a modest endurance lift to an untrained adult who is also starting to exercise. Turkey tail's pharmaceutical extract lives in oncology, not your morning routine. Reishi for sleep and chaga for antioxidant longevity are the tradition-rich, trial-poor end of the shelf. The catch under all of it: most retail capsules are mushroom mycelium grown on rice or oats and sold by combined polysaccharide content — most of which is the grain's starch, not the β-glucan that does the work.

All five share one thing: their cell walls are built from long sugar chains called β-glucans, the same family of fibre that makes oat porridge filling, and the same family human immune cells have evolved to recognise. A receptor on macrophages and other front-line immune cells (dectin-1) latches onto β-glucan and reads it as a microbial signature, which sets off a measured response: cytokine release, natural-killer-cell activation, a small push toward responding more vigorously to threats later Wachtel-Galor 2011. That shared mechanism is roughly the same whether the β-glucan comes from reishi, turkey tail, or even yeast.

What separates the species is the second layer of chemistry. Reishi adds a class of bitter steroids called ganoderic acids, which calm inflammation in cell studies and inhibit platelet stickiness. Cordyceps adds cordycepin, a near-twin of adenosine — one of the molecules the body uses to signal "running low on energy." Turkey tail's standout is a protein-bound β-glucan called PSK, which has been on the Japanese national drug formulary as a chemotherapy adjuvant since 1977 Eliza et al. 2012.

The species with the most distinctive mechanism in the entire supplement world is lion's mane. Its bioactive small molecules — hericenones from the cap and stem, erinacines from the underground mycelium — stimulate nerve growth factor, the protein that keeps adult neurons alive and growing new branches Kawagishi et al. 1994. The erinacines cross the blood-brain barrier in animals and lift nerve growth factor in the hippocampus and the brainstem regions that wire mood Spelman et al. 2017. No other functional mushroom can credibly claim that route into the brain.

What the trials actually show

The category's flagship study is small, Japanese, and more than fifteen years old. Thirty adults in their fifties to seventies with creeping cognitive slippage took a gram of dried lion's mane three times a day or a placebo. By week eight, the lion's mane group started scoring better on a standard dementia-screening test. By week sixteen, the gap was clear. Four weeks after they stopped, the gain regressed.

A 2019 trial in older adults without dementia repeated the cognitive lift at a similar dose over twelve weeks Saitsu et al. 2019. A four-week trial in perimenopausal women found small drops in depression and anxiety scores on a baked-good vehicle Nagano et al. 2010. These are the strongest trials lion's mane has, and they share one shape: small samples, single country, single research group, no large independent replication. Nothing has tested the population that buys most of the powder — healthy twenty- and thirty-somethings looking for sharper focus.

Cordyceps' base is similar in size, different in subject. Twenty sedentary older adults took fermented Cordyceps sinensis mycelium or placebo for twelve weeks; the cordyceps group lifted their ventilatory threshold by about ten percent while the placebo group did not budge Chen et al. 2010. A follow-up using Cordyceps militaris in untrained adults found the lift only kicked in after three weeks of daily dosing — acute, day-of dosing did nothing Hirsch et al. 2017. The effect is real, small, slow, and concentrated in people who were not training to begin with. Trained athletes mostly do not see it.

Turkey tail's evidence is the strongest in the category, and the most narrowly applicable. A patented β-glucan extract called PSK, isolated by a Japanese pharmaceutical company in the 1970s, is part of standard adjuvant care for resected gastric cancer in Japan. A meta-analysis pooling eight randomised trials in over 8,000 patients found that adding PSK to chemotherapy cut the death hazard by eleven to twelve percent over chemotherapy alone Oba et al. 2007. A broader analysis across thirteen trials and several cancer types showed a similar nine percent reduction Eliza et al. 2012. A small dose-finding trial in women after radiation for breast cancer restored natural-killer-cell counts at the higher doses Torkelson et al. 2012. This is real, it is in the right range for a working pharmaceutical, and it lives in clinical oncology under a clinician — not on the supplement shelf.

Reishi's reputation runs ahead of its evidence. The Cochrane review of reishi in cancer pooled five trials and judged the evidence "low quality" — modest immune-marker shifts when added to chemotherapy, no clear effect when used alone Jin et al. 2016. The popular sleep and stress claim, the reason most reishi gets bought, has essentially no human trial data behind it. It rides on rodent sleep-architecture studies and centuries of Chinese-medicine convention Wachtel-Galor 2011. The mechanism is plausible; the trial is missing.

Chaga is the most extrapolated of the five. Its antioxidant numbers in the lab are spectacular — among the highest measured for any food — and rodent studies show suppression of inflammatory signalling. Controlled human trials are essentially absent. What does exist is a handful of case reports of acute kidney injury, including a fatal one, after months of daily chaga tea: the mushroom is high in oxalates, which can crystallise in the kidneys at chronic high intake Sumi et al. 2014. The signal-to-noise on chaga, at the population level, is currently poor.

What the bottle is actually selling you

The single biggest thing most guides get wrong is taking the label at face value. Most retail mushroom supplements are made not from the fruiting body — the cap and stem you would recognise as a mushroom — but from mycelium, the root-like web that grew it, cultivated on a bed of rice or oats. When the manufacturer measures "polysaccharide content," what they get is largely the grain's starch, not the mushroom's β-glucan. Independent assays of US-retail products routinely find the actual β-glucan content somewhere between one and fifty percent of the labelled total McCleary & Draga 2016. A label that proudly says "30% polysaccharides" can be 28% rice and 2% mushroom.

The second misconception is that the five species are roughly interchangeable. They share β-glucans; everything else is species-specific. A reishi capsule does not deliver lion's mane's nerve-growth-factor effect, and a lion's mane capsule does not deliver turkey tail's tumour-adjuvant chemistry. The "ten-mushroom blend" capsules sold as complete immune support are usually a thin sub-gram of each species, well below the doses any trial used.

The third is that "natural" rules out harm. Reishi case reports include severe hepatic failure where no other cause could be found Wanmuang et al. 2007. Chaga has caused acute kidney injury through oxalate buildup Sumi et al. 2014. Reishi's triterpenes inhibit platelet stickiness, which can compound with warfarin or aspirin to cause bleeding. None of this is common; none of it is zero.

What you lose by skipping, and what you risk by trying

Most readers who skip the entire category will not notice it. There is no silent damage accumulating in a thirty-five-year-old's afternoons that two grams a day of lion's mane fixes. The honest stakes of opting out are mostly nothing — except in two narrow cases. The first is a midlife adult who has started to notice names slipping, the second cup of coffee not landing the way it used to, the same paragraph read twice: lion's mane has a small but real shot at slowing that drift. The second is someone on chemotherapy whose oncologist mentions turkey tail's PSK: that decision is a real one, and skipping it without asking is leaving evidence on the table.

The stakes of opting in are also small but not zero. The most concrete is money: a quality, dual-extracted product at trial-equivalent dose runs two to four hundred dollars a year per species. The next is the standardisation problem — a real share of money spent on cheaper brands buys grain starch. The medical risks live in the contraindications below: bleeding for someone on a blood thinner, kidney injury on long daily chaga, the occasional liver case report on reishi. None catastrophic for the median person, none ignorable for the wrong reader.

If you decide yes

Each species is its own protocol; the trial doses are not interchangeable and the product class matters more than the number on the front of the bottle.

  • Lion's mane. One to three grams a day of dual-extracted fruiting body. The Mori trial used three; effects took eight to sixteen weeks to surface and regressed within a month of stopping Mori et al. 2009. Below a gram a day is below the range that has been tested.
  • Cordyceps. One to four grams a day of mycelial extract. The Cs-4 trial used a single gram; the Cordyceps militaris trial used three to four. Expect three weeks before any effect Hirsch et al. 2017.
  • Reishi. One and a half to three grams a day of dual-extracted product. No good human dose-response data exists; the popular sleep claim has no trial backing it Wachtel-Galor 2011.
  • Turkey tail (over-the-counter). Three to nine grams a day of dual-extracted fruiting body — the dose range in the breast-cancer Phase I trial Torkelson et al. 2012. Anyone considering turkey tail as a chemotherapy adjuvant should make that decision with their oncologist, not at a supplement shop.
  • Chaga. No validated dose. Long daily chaga tea concentrates oxalates; treat as occasional, not standing Sumi et al. 2014.

Extraction matters more than the gram count on the bottle. β-glucans are water-soluble; triterpenes (the ganoderic acids in reishi) are alcohol-soluble. A dual-extracted product — both hot water and ethanol — captures both classes. A ground-mushroom capsule extracts neither well, because both classes sit inside chitin cell walls that human digestion does not fully break down Friedman 2015.

When not to

How to actually buy one

Three things separate a product worth the money from one that is not. First, fruiting body, not mycelium-on-grain — read the ingredient panel. Second, a published β-glucan assay for the lot in your bottle, not a "total polysaccharide" number (which silently combines the mushroom's β-glucan with the grain substrate's starch) McCleary & Draga 2016. Third, "dual-extracted" stated on the label, hot water and ethanol both.

A handful of suppliers do this consistently; the rest of the retail market does not. Expect a quality dual-extracted lion's mane or reishi at trial-equivalent dose to run twenty to forty dollars a month per species. Wild Cordyceps sinensis from the Tibetan plateau is among the most expensive natural products on earth at thousands of dollars per kilogram; almost everything sold as "cordyceps" in the West is Cordyceps militaris grown on a substrate, comparably priced to the others.

The pharmaceutical form of turkey tail's PSK is prescription-only in Japan and not legally sold outside it. A retail turkey tail bottle and PSK proper share β-glucan chemistry but not the regulatory pedigree behind the cancer-adjuvant trials.

What you would actually notice if it works

If lion's mane is going to land, it lands slowly. Three or four months in, on a steady gram or three a day, the foggy hour after lunch becomes an ordinary one. The name on the tip of your tongue arrives without the second-long search. You walk back into the room you came for and remember why. Mood settles a touch — quieter, less brittle in the evenings. Not a smart drug; more like a slow brake on a drift you were starting to feel Mori et al. 2009, Saitsu et al. 2019. Stop taking it, and a month later the drift resumes. The effect is real and modest; nobody around you will comment on a transformed person.

Cordyceps' payoff, if any, is for someone re-entering endurance work. Three or four weeks in, the third mile of a Sunday run is a little less brutal than the first one was last month — a modest few percent on top of the much larger gains the running itself is producing Chen et al. 2010. Do not expect it to surface on race day. The friend who notices the change will notice it in the running, not the capsule.

Turkey tail's real payoff is not on the supplement shelf. It is in oncology, measured not in afternoon energy but in survival hazard ratios over years — a roughly ten percent reduction on top of conventional adjuvant chemotherapy, in the specific cancers PSK has been trialled in Oba et al. 2007, Eliza et al. 2012. The payoff is real; it belongs to a different kind of decision.

Reishi for sleep, chaga for "antioxidant longevity" — expect to notice nothing, and you may well be right. The bottle has been the marketing more than the molecule.

What might do the job better

Most of the claims that pull a reader to medicinal mushrooms have stronger-evidence interventions in the same lane. For cognition in midlife, creatine monohydrate at three to five grams a day has a far larger trial base than lion's mane and is several times cheaper. For acute focus, caffeine paired with L-theanine is much better-studied. For endurance, the cordyceps effect is dwarfed by what an actual training programme delivers in the same six weeks. For sleep, sleep hygiene and cognitive behavioural therapy for insomnia have the kind of evidence reishi can only gesture at.

For the β-glucan immune signal itself, oats and barley deliver the same cell-wall fibre family in food form, without buying capsules. Yeast β-glucan, distilled from baker's yeast, has its own RCT base for healthy-adult immune support and is the better-trialled β-glucan supplement.

The honest reading: mushrooms are a reasonable complementary play in one or two narrow cases. They are rarely the strongest move in their own lane.

Culinary mushrooms eaten as food — button, oyster, shiitake, portobello — are a different category, with ergothioneine, dietary fibre, and (in UV-exposed mushrooms) vitamin D doing work the extract aisle does not. Yeast β-glucan is its own supplement with its own RCT base. Psilocybin mushrooms are a different substance entirely — neither food nor functional supplement, with their own evidence, legal status, and risk profile.

·
522